TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26721139

Group type: EXPERIMENTAL
Intervention: Float needle retention for 6 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Float needle retention for 12 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Float needle retention for 24 hours
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medication (75 mg voltaren tablet orally every day for four days)
Number of subjects: 120
Study: 23415775

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 789
Study: 21859991

Group type: EXPERIMENTAL
Intervention: BIBF 1120 250 mg, twice per day, continuously for 36 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: BIBF 1120 250 mg
Number of subjects: 83
Study: 19329838

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 17356040

Group type: EXPERIMENTAL
Intervention: Intravenous antioxidant therapy (n-acetylcysteine, selenium, vitamin C)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 16597660

Group type: EXPERIMENTAL
Intervention: Printed booklets with personalised information from the patient's medical record plus selected general information
Number of subjects: 400

Group type: COMPARATOR
Intervention: Printed booklets with general information from CancerBACUP
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Larger booklets produced automatically
Number of subjects: 400

Group type: COMPARATOR
Intervention: Printed booklets produced interactively
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Printed booklets with additional advice on anxiety management
Number of subjects: 400

Group type: COMPARATOR
Intervention: Printed booklets without additional advice on anxiety management
Number of subjects: 400
Study: 12930177

Group type: EXPERIMENTAL
Intervention: Resistance training (R, n = 9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Endurance training (E, n = 8)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Concurrent resistance and endurance training (C, n = 9)
Number of subjects: 26
Study: 10751378

Group type: EXPERIMENTAL
Intervention: School-based programme teaching about burns and scalds hazards
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control school (no intervention)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Take-home exercise
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Overall programme effectiveness
Number of subjects: 190
Study: 8657760

Group type: EXPERIMENTAL
Intervention: Corticosteroid medication
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 30
Study: 1900101

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Placebo (for encainide)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Placebo (for flecainide)
Number of subjects: 1498
Study: 6439090

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (3 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 31366396

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine during a preliminary 7-day loading phase and for eight consecutive days following a single bout of intense muscle-damaging exercise.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo during a preliminary 7-day loading phase and for eight consecutive days following a single bout of intense muscle-damaging exercise.
Number of subjects: 0
Study: 26897125

Group type: EXPERIMENTAL
Intervention: Hazelnuts (42 g)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chocolate (50 g)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Potato crisps (50 g)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No added snack food
Number of subjects: 102
Study: 25652757

Group type: EXPERIMENTAL
Intervention: Stanozolol 2 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (leg compression alone)
Number of subjects: 44
Study: 22699838

Group type: EXPERIMENTAL
Intervention: PEG-P (1.5 g/kg divided twice per day for 2 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Senna (15 mL daily for ages 6-12 or 30 mL daily for ages 12-21 for 2 days)
Number of subjects: 30
Study: 21362056

Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance (SE) training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Endurance (E) training
Number of subjects: 14
Study: 19563006

Group type: EXPERIMENTAL
Intervention: Perioperative administration of celecoxib (200 mg twice daily, starting 3 days before TKA and extending to 5 days postoperatively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perioperative administration of celecoxib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (postoperative administration of celecoxib, 200 mg twice daily, starting 2 hours after TKA and extending to 5 days postoperatively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 16405543

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 15546434

Group type: EXPERIMENTAL
Intervention: Low-fat plant sterol ester (PSE)‐enriched spread (21 g day(‐1))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11342469

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) using gadolinium-diethylenetriamine pentaacetic acid bismethylamide (Omniscan; 0.1 mmol/kg injected at 3 mL/s IV) during hyperemia (dipyridamole 0.56 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Positron Emission Tomography (PET)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Quantitative Coronary Angiography
Number of subjects: 48
Study: 9246252

Group type: EXPERIMENTAL
Intervention: Treatment focusing on sexual dysfunction
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Treatment focusing on interpersonal problems
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination of both sexual dysfunction and interpersonal problems
Number of subjects: 69

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 69
Study: 8280561

Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enflurane induction and maintenance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enflurane anaesthesia without hypotension (Control)
Number of subjects: 40
Study: 3518552

Group type: COMPARATOR
Intervention: Protocol I (0 mg fentanyl)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Protocol II (0.05 mg fentanyl)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Protocol III (0.1 mg fentanyl)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Protocol IV (0.15 mg fentanyl)
Number of subjects: 159
Study: 31157949

Group type: EXPERIMENTAL
Intervention: 10 kHz high frequency stimulation (HFS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lower frequency stimulation (LFS) below 1500 Hz
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall trial success rate
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Subjects with predominant low back pain
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Subjects with leg pain ≥ low back pain
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Infection rate
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Withdrawal and explantation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Electrode migrations
Number of subjects: 99
Study: 30281796

Group type: EXPERIMENTAL
Intervention: Baseline MAT-sf scores
Number of subjects: 1574
Study: 28803119

Group type: EXPERIMENTAL
Intervention: Low-intensity cycling (∼40%HRR) for 15 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition (sitting quietly on the bike for 15 minutes)
Number of subjects: 24
Study: 24630745

Group type: EXPERIMENTAL
Intervention: Interdisciplinary occupational and sport therapy intervention for dementia patients suffering from apathy, provided once a week for 10 months.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 117
Study: 22733197

Group type: EXPERIMENTAL
Intervention: Laparoscopic left hemicolectomy with preservation of the inferior mesenteric artery (IMA)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Laparoscopic left hemicolectomy with IMA sectioned below the left colic artery
Number of subjects: 107
Study: 21209618

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 32
Study: 18080713

Group type: EXPERIMENTAL
Intervention: Pneumatic balloon dilatation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 53
Study: 16752834

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cell transplantation (more than 1 X 10(8)) in group A
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (less than 1 X 10(5)) in group B
Number of subjects: 22
Study: 12854148

Group type: EXPERIMENTAL
Intervention: lamivudine+interferon
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 34

Group type: COMPARATOR
Intervention: interferon
Number of subjects: 34
Study: 12652617

Group type: EXPERIMENTAL
Intervention: all-trans-retinoic acid (ATRA) at a dosage of 25 mg/m(2)/day
Number of subjects: 14
Study: 10853849

Group type: EXPERIMENTAL
Intervention: 1,250 mg azithromycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8661791

Group type: EXPERIMENTAL
Intervention: Argon coagulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard electrocoagulation
Number of subjects: 24
Study: 1991527

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC, 7‐7‐7)
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Switch to monophasic pill (1/35)
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Control group (various OCs)
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: 0.5/35 monophasic pill
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: 1/35 monophasic pill
Number of subjects: 1259
Study: 6826814

Group type: EXPERIMENTAL
Intervention: Cephalexin (twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dicloxacillin (four times daily)
Number of subjects: 70
Study: 31362541

Group type: EXPERIMENTAL
Intervention: Invasive management (n=31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medical management (n=29)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 30015146

Group type: EXPERIMENTAL
Intervention: Males + estrogenized females (EFEM-MAR)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Males + estrogenized females (EFEM-APR)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Males + non-treated-anestrous females (CONT-MAR)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Males + non-treated-anestrous females (CONT-APR)
Number of subjects: 92
Study: 26818376

Group type: EXPERIMENTAL
Intervention: Gum chewing (one stick of sugarless gum during the pause interval of drinking polyethylene glycol solution)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (drank polyethylene glycol solution according to the general protocol)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 131
Study: 25066331

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg per day tapered) and fludrocortisone (50 μg tablet once per day)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 336
Study: 23202523

Group type: EXPERIMENTAL
Intervention: HAI-05 vaccine (15, 45, and 90 µg) with Alhydrogel® (0.75 mg aluminum per dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAI-05 vaccine (90 µg) without Alhydrogel®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20214068

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding at Baihui (GV 20), Shenting (GV 24), Sishencong (EX-HN 1) combined with massage of sole
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oral administration of Estazolam
Number of subjects: 49
Study: 17442905

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 638
Study: 16137240

Group type: EXPERIMENTAL
Intervention: Early mobilisation plus deep breathing and coughing exercises
Number of subjects: 56

Group type: COMPARATOR
Intervention: Early mobilisation only
Number of subjects: 56
Study: 12404512

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from MS patients with 0.1 mM ITU (specific iNOS inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from MS patients with 1 mM L-NMMA (nonisoform specific NOS inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from MS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) from controls
Number of subjects: 0
Study: 9887852

Group type: EXPERIMENTAL
Intervention: Transmural home care programme
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study: 7625352

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (HC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet combined with exercise training (HC-EX)
Number of subjects: 20
Study: 2122855

Group type: EXPERIMENTAL
Intervention: Early PTCA (24‐72 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed PTCA (8‐10 days)
Number of subjects: 50
Study: 354826

Group type: EXPERIMENTAL
Intervention: L-alpha-methyldopa hydrazine
Number of subjects: 8

Group type: COMPARATOR
Intervention: alpha-methyldopa
Number of subjects: 8
Study: 31340316

Group type: EXPERIMENTAL
Intervention: Strength program with TheraBands® for 12 weeks, with two weekly sessions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Strength program with TheraBands®
Number of subjects: 26
Study: 28899491

Group type: EXPERIMENTAL
Intervention: Selenium and Lycopene supplementation (Group A)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 209
Study: 25981709

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) with target inflation pressures of 70 mmHg for 1 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 20
Study: 22981376

Group type: EXPERIMENTAL
Intervention: Exercise therapy (2 hours weekly for six months)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Occupational therapy (control for patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Life-as-usual (control for healthy controls)
Number of subjects: 118
Study: 21232801

Group type: EXPERIMENTAL
Intervention: IVTA plus laser
Number of subjects: 84

Group type: COMPARATOR
Intervention: Laser only
Number of subjects: 84
Study: 18070232

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32
Study: 17058778

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 0
Study: 12943436

Group type: EXPERIMENTAL
Intervention: Active infant orthopedic treatment with Latham dentomaxillary alignment (DMA) appliance inserted at 5 to 6 weeks of age.
Number of subjects: 40

Group type: COMPARATOR
Intervention: No active infant orthopedic treatment (nonorthopedic group).
Number of subjects: 40
Study: 11711509

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of amiloride and spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9164679

Group type: EXPERIMENTAL
Intervention: Primary medical therapy (PMT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Adjuvant chemoendocrine therapy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Measurement by enzyme immunoassay (EIA)
Number of subjects: 147
Study: 8047746

Group type: EXPERIMENTAL
Intervention: Surrogate information time for monitoring treatment effects
Number of subjects: 0
Study: 3310870

Group type: EXPERIMENTAL
Intervention: alpha‐2a interferon at 30 X 10(6) IU/ml
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: alpha‐2a interferon at 10 X 10(6) IU/ml
Number of subjects: 94

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study: 2100737

Group type: EXPERIMENTAL
Intervention: 100 mg aqueous extract (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg standardized extract (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactose control (Group B)
Number of subjects: 60
Study: 775694

Group type: EXPERIMENTAL
Intervention: Immediate ambulation and discharge after cataract surgery
Number of subjects: 100
Study: 31703670

Group type: EXPERIMENTAL
Intervention: Transmural Trauma Care Model (TTCM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 83
Study: 28252190

Group type: EXPERIMENTAL
Intervention: Vitamin D pearls
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo pearls
Number of subjects: 50
Study: 25543971

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day (or 5 mg/kg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 23953594

Group type: EXPERIMENTAL
Intervention: 200 μg/day of vitamin K1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21430088

Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol · kg(‐1) · min(‐1))
Number of subjects: 9
Study: 19283541

Group type: EXPERIMENTAL
Intervention: Public service announcements (PSAs) with celebrity character appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public service announcements (PSAs) with noncelebrity character appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-involvement message content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-involvement message content
Number of subjects: 0
Study: 17374063

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation (UVB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical high-potency corticosteroid before UVB exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 8
Study: 12638566

Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg x kg(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg x kg(‐1)
Number of subjects: 20
Study: 11228063

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 252
Study: 8896779

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1796130

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neuroleptics (on treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neuroleptics (off treatment)
Number of subjects: 29
Study: 6366804

Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 222

Group type: COMPARATOR
Intervention: Long-acting propranolol
Number of subjects: 222
Study: 31825525

Group type: EXPERIMENTAL
Intervention: Abdominal paracentesis and intraperitoneal infusion of catumaxomab
Number of subjects: 245

Group type: COMPARATOR
Intervention: Abdominal paracentesis alone
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Catumaxomab infusion
Number of subjects: 245
Study: 28650782

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus acidophilus ATCC 4356 and Bifidobacterium bifidum ATCC 29521 (200 g daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gums (two gums three times daily after each meal; total xylitol content: 5.58 g daily)
Number of subjects: 50
Study: 25886945

Group type: EXPERIMENTAL
Intervention: Culturally-relevant Facebook and text message intervention (FI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-culturally tailored print-based intervention (PI)
Number of subjects: 29
Study: 23296812

Group type: COMPARATOR
Intervention: COLD (15°C)
Number of subjects: 198

Group type: COMPARATOR
Intervention: NEUTRAL (21°C)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: HOT (30°C)
Number of subjects: 198

Group type: COMPARATOR
Intervention: DIM (11 lx)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: BRIGHT (433 lx)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Temperature (15°C to 30°C)
Number of subjects: 198
Study: 21596326

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 2797

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2797
Study: 19635898

Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg weekly for 6 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16943671

Group type: EXPERIMENTAL
Intervention: Operation plus TACE and PVC (group C)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Operation only (group A)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Operation plus TACE (group B)
Number of subjects: 131
Study: 15235332

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sodium chloride (placebo)
Number of subjects: 15
Study: 10847537

Group type: EXPERIMENTAL
Intervention: Resorbable polylactic acid (PLA) barrier
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-resorbable polytetrafluoroethylene (e-PTFE) barrier
Number of subjects: 19